Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Innate Pharma (IPHA), Emergent Biosolutions (EBS)

Tipranks - Tipranks - Tue Apr 21, 5:46AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Innate Pharma (IPHA), Emergent Biosolutions (EBS) and Vertex Pharmaceuticals (VRTX) with bullish sentiments.

Claim 30% Off TipRanks

Innate Pharma (IPHA)

In a report released yesterday, Jeet Mukherjee from BTIG maintained a Buy rating on Innate Pharma, with a price target of $8.00. The company’s shares closed last Friday at $1.66, close to its 52-week low of $1.29.

According to TipRanks.com, Mukherjee is a 5-star analyst with an average return of 21.7% and a 63.5% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Aardvark Therapeutics, Inc., and Perspective Therapeutics. ;'>

Innate Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, representing a 303.7% upside. In a report issued on April 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.

See the top stocks recommended by analysts >>

Emergent Biosolutions (EBS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions, with a price target of $12.00. The company’s shares closed last Friday at $8.81.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 26.4% and a 60.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $612.00. The company’s shares closed last Friday at $441.20.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.8% and a 55.9% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Arvinas Holding Company, and Crispr Therapeutics AG. ;'>

Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $560.50, implying a 26.9% upside from current levels. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $541.00 price target.

Read More on IPHA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).